Halozyme, Inc.’s Post

View organization page for Halozyme, Inc., graphic

18,864 followers

Yesterday, Halozyme announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees. The new patent is licensed under all of Halozyme's ENHANZE® licenses. It will be validated in 37 European countries and expires on March 6, 2029. Halozyme discussed the new European patent and provided an update to its 2024 financial guidance and 5-year financial outlook on a conference call earlier today. To access the webcast and presentation, please visit https://ow.ly/QIQ050Sb7Qt. The press release announcing the patent can be found here: https://ow.ly/s2lW50Sb7Qs

  • No alternative text description for this image
Yogesh Tagad

Global Business Development Manager @ Devsynthesis India Pvt. Ltd. | Small Molecules | Discovery Chemistry| Process development

2mo

Congratulations on the grant of the European Patent No. 4269578, Halozyme! This achievement truly reflects the innovative spirit and dedication of the team. Looking forward to seeing the continued success and growth of Halozyme's ENHANZE® rHuPH20 product in the European market.

Like
Reply
Pian Sun

CNIO - Spanish National Cancer Research Centre - PhD Student

1mo

Cogratulations!!! Is it any chance that we collaborate this enzyme in genetically mouse engineer? until now, we have very promising data from Dr Barbacid Mariano´s lab. looking forward to your contact!(psun@cnio.es)

Like
Reply
Marci Knight

Director, Talent Acquisition

2mo

Great news! This has a huge impact on our growth potential. Please check out all our job postings and reach out to me!

See more comments

To view or add a comment, sign in

Explore topics